Related Experiment Videos

Intrathecal midazolam versus intrathecal morphine in orofacial nociception: an experimental study in rats

L Aigouy1, J C Fondras, J Pajot

  • 1Laboratoire de Physiologie Orofaciale, U.E.R. Odontologie, Clermont-Ferrand, France.

Neuroscience Letters
|May 11, 1992
PubMed

Insights

Intrathecal midazolam and morphine effectively reduced pain responses in rats. Midazolam also demonstrated efficacy in reducing the initial pain phase, suggesting analgesic properties for long-lasting pain.

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Orofacial pain is a significant clinical challenge.
  • Opioid analgesics like morphine are commonly used but have limitations.
  • Exploring non-opioid analgesics for orofacial pain is crucial.

Purpose of the Study:

  • To compare the antinociceptive effects of intrathecal midazolam and morphine in a rat orofacial pain model.
  • To investigate midazolam's potential as an analgesic for different pain phases.

Main Methods:

  • Utilized an adapted formalin test in the orofacial region of rats.
  • Administered intrathecal midazolam (15 and 30 micrograms) and intrathecal morphine (30 micrograms).
  • Assessed the reduction in nociceptive responses during the first and second phases of the pain test.

Main Results:

  • Both intrathecal midazolam and morphine significantly reduced nociception in the second phase of the formalin test.
  • Intrathecal midazolam at 30 micrograms also attenuated the nociceptive response in the first phase.
  • Midazolam demonstrated broader antinociceptive effects compared to morphine in this model.

Conclusions:

  • Intrathecal midazolam exhibits significant antinociceptive properties in orofacial pain models.
  • Midazolam's ability to affect both phases of the formalin test suggests potential for treating acute and persistent pain.
  • These findings support further investigation of midazolam as a therapeutic agent for orofacial pain.

Related Concept Videos